BIGT.L vs. BTEK.L
BIGT.L (L&G Pharma Breakthrough UCITS ETF) and BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) are both Health & Biotech Equities funds tracking the NASDAQ Biotechnology TR USD, from Legal & General and iShares respectively. Both are passively managed. Over the past 5 years, BIGT.L returned 2.49%/yr vs 5.85%/yr for BTEK.L. Their correlation of 0.83 suggests significant overlap in exposure. BIGT.L charges 0.49%/yr vs 0.35%/yr for BTEK.L.
Performance
BIGT.L vs. BTEK.L - Performance Comparison
Loading charts...
Different Trading Currencies
BIGT.L is traded in GBp, while BTEK.L is traded in GBP. To make them comparable, the BTEK.L values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, BIGT.L achieves a -0.70% return, which is significantly lower than BTEK.L's 4.86% return.
BIGT.L
- 1D
- 2.65%
- 1M
- -4.10%
- YTD
- -0.70%
- 6M
- -3.42%
- 1Y
- 26.08%
- 3Y*
- 2.96%
- 5Y*
- 2.49%
- 10Y*
- —
BTEK.L
- 1D
- 3.56%
- 1M
- 2.25%
- YTD
- 4.86%
- 6M
- 2.70%
- 1Y
- 43.15%
- 3Y*
- 10.19%
- 5Y*
- 5.85%
- 10Y*
- —
BIGT.L vs. BTEK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BIGT.L L&G Pharma Breakthrough UCITS ETF | -0.70% | 27.03% | -3.16% | -14.88% | 2.68% | -2.30% | 23.89% | 9.47% | -1.85% |
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF | 4.86% | 23.81% | -0.32% | 0.33% | -1.55% | 0.90% | 23.11% | 21.63% | -8.49% |
Correlation
The correlation between BIGT.L and BTEK.L is 0.84, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.84 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.80 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.81 |
Correlation (All Time) Calculated using the full available price history since Jan 26, 2018 | 0.83 |
The correlation between BIGT.L and BTEK.L has been stable across timeframes, ranging from 0.80 to 0.84 - a consistent structural relationship.
BIGT.L vs. BTEK.L - Sectors Allocation Comparison
Sectors
BIGT.L
BTEK.L
Healthcare
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
BIGT.L
BTEK.L
Basic Materials
BIGT.L
BTEK.L
-
Communication Services
BIGT.L
-
BTEK.L
-
Consumer Cyclical
BIGT.L
-
BTEK.L
-
Consumer Defensive
BIGT.L
-
BTEK.L
-
Energy
BIGT.L
-
BTEK.L
-
Financial Services
BIGT.L
-
BTEK.L
-
Industrials
BIGT.L
-
BTEK.L
-
Real Estate
BIGT.L
-
BTEK.L
-
Technology
BIGT.L
-
BTEK.L
-
Utilities
BIGT.L
-
BTEK.L
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIGT.L vs. BTEK.L — Risk / Return Rank
BIGT.L
BTEK.L
BIGT.L vs. BTEK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF (BIGT.L) and iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIGT.L | BTEK.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.85 | ||
| Sortino ratioReturn per unit of downside risk | -1.09 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.38 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 2.57 | 6.23 | -3.66 |
| Martin ratioReturn relative to average drawdown | 7.42 | 17.55 | -10.14 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BIGT.L | BTEK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.39 | 2.24 | -0.85 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.15 | 0.29 | -0.14 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.31 | -0.09 |
Drawdowns
BIGT.L vs. BTEK.L - Drawdown Comparison
The maximum BIGT.L drawdown since its inception was -30.23%, roughly equal to the maximum BTEK.L drawdown of -30.86%. Use the drawdown chart below to compare losses from any high point for BIGT.L and BTEK.L.
Loading charts...
Drawdown Indicators
| BIGT.L | BTEK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.23% | -30.86% | +0.63% |
Max Drawdown (1Y)Largest decline over 1 year | -9.93% | -6.89% | -3.04% |
Max Drawdown (3Y)Largest decline over 3 years | -23.09% | -26.34% | +3.25% |
Max Drawdown (5Y)Largest decline over 5 years | -30.23% | -30.86% | +0.63% |
Current DrawdownCurrent decline from peak | -5.41% | -1.86% | -3.55% |
Average DrawdownAverage peak-to-trough decline | -10.57% | -10.04% | -0.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.45% | 2.45% | +1.00% |
Volatility
BIGT.L vs. BTEK.L - Volatility Comparison
The current volatility for L&G Pharma Breakthrough UCITS ETF (BIGT.L) is 6.35%, while iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) has a volatility of 6.91%. This indicates that BIGT.L experiences smaller price fluctuations and is considered to be less risky than BTEK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIGT.L | BTEK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.35% | 6.91% | -0.56% |
Volatility (6M)Calculated over the trailing 6-month period | 14.10% | 14.67% | -0.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 18.38% | 19.14% | -0.76% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 16.86% | 20.08% | -3.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 18.38% | 21.71% | -3.33% |
BIGT.L vs. BTEK.L - Expense Ratio Comparison
BIGT.L has a 0.49% expense ratio, which is higher than BTEK.L's 0.35% expense ratio.
Dividends
BIGT.L vs. BTEK.L - Dividend Comparison
Neither BIGT.L nor BTEK.L has paid dividends to shareholders.
Frequently Asked Questions
BIGT.L and BTEK.L have a correlation of 0.84, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BTEK.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BTEK.L is cheaper with a 0.35% expense ratio, compared with 0.49% for BIGT.L.
Both ETFs track NASDAQ Biotechnology TR USD. They also come from different issuers: Legal & General and iShares. Their fees differ too: 0.49% for BIGT.L and 0.35% for BTEK.L.
Find the right allocation for BIGT.L and BTEK.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer